Literature DB >> 9869159

Retrospective neuropathological review of prion disease in UK haemophilic patients.

C A Lee1, J W Ironside, J E Bell, P Giangrande, C Ludlam, M M Esiri, J E McLaughlin.   

Abstract

In 1996, the CJD surveillance unit in Edinburgh, UK described nvCJD which was thought to be the human equivalent of bovine spongiform encephalopathy (BSE). The identification of prion protein in the tonsil of an affected individual has raised the question of transmission of nvCJD via blood products. This study examines the post mortem brains of 33 patients who were treated with clotting factor concentrate of predominately UK donor source during the years 1962-1995. The brains were examined by conventional histological methods and also for the prion protein using monoclonal antibodies KG9 and 3F4. No evidence of spongiform encephalopathy was found and the immunocytochemistry was negative for PrP in all cases. It is concluded that, at present, there is no evidence for the transmission of nvCJD via clotting factor concentrate to patients with haemophilia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9869159

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  4 in total

Review 1.  Safety and availability of immunoglobulin replacement therapy in relation to potentially transmissable agents. IUIS Committee on Primary Immunodeficiency Disease. International Union of Immunological Societies.

Authors:  H M Chapel
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

2.  Prion protein-specific antibodies that detect multiple TSE agents with high sensitivity.

Authors:  Sandra McCutcheon; Jan P M Langeveld; Boon Chin Tan; Andrew C Gill; Christopher de Wolf; Stuart Martin; Lorenzo Gonzalez; James Alibhai; A Richard Alejo Blanco; Lauren Campbell; Nora Hunter; E Fiona Houston
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

Review 3.  Ensuring the biologic safety of plasma-derived therapeutic proteins: detection, inactivation, and removal of pathogens.

Authors:  Kang Cai; Todd M Gierman; JoAnn Hotta; Christopher J Stenland; Douglas C Lee; Dominique Y Pifat; Steve R Petteway
Journal:  BioDrugs       Date:  2005       Impact factor: 5.807

4.  Safety procedures of coagulation factors.

Authors:  J I Jorquera
Journal:  Haemophilia       Date:  2007-12       Impact factor: 4.287

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.